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Abstract 
Hyperglycemia augments formation of intracellular reactive oxygen species (ROS) with associated 
mitochondrial damage and increased risk of insulin resistance in type 2 diabetes. We examined 
whether quercetin could reverse chronic high glucose-induced oxidative stress and mitochondrial 
dysfunction. Following long-term high glucose treatment, complex I activity was significantly 
decreased in isolated mitochondria from HepG2 cells. Quercetin dose-dependently recovered complex 
I activity and lowered cellular ROS generation under both high and normal glucose conditions. 
Respirometry studies showed that quercetin could counteract the detrimental increase in inner 
mitochondrial membrane proton leakage resulting from high glucose while it increased oxidative 
respiration, despite a decrease in electron transfer system (ETS) capacity, and lower non-ETS oxygen 
consumption. A quercetin-stimulated increase in cellular NAD+/NADH was evident within 2 h and a 
two-fold increase in PGC-Į mRNA within 6 h, in both normal and high glucose conditions. A 
similar pattern was also found for the mRNA expression of the repulsive guidance molecule b 
(RGMB) and its long non-coding RNA (lncRNA) RGMB-AS1 with quercetin, indicating a potential 
change of the glycolytic phenotype and suppression of aberrant cellular growth which is characteristic 
of the HepG2 cells. Direct effects of quercetin on PGC-1Į activity were minimal, as quercetin only 
weakly enhanced PGC-ĮELQGLQJWR33$5Įin vitro at higher concentrations. Our results suggest that 
quercetin may protect mitochondrial function from high glucose-induced stress by increasing cellular 
NAD+/NADH and activation of PGC-Į-mediated pathways. Lower ROS in combination with 
improved complex I activity and ETS coupling efficiency under conditions of amplified oxidative 
stress could reinforce mitochondrial integrity and improve redox status, beneficial in certain metabolic 
diseases.  
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Abbreviations 
AmA ± antimycin A; AMPK ± adenosine monophosphate-activated protein kinase; CoQ ± coenzyme 
Q10; DCF ± 2ƍ,7ƍ-dichlorofluorescin; DCFH-DA ± 2ƍ,7ƍ-dichlorofluorescin diacetate; ddPCR ± droplet 
digital PCR; ETS ± electron transfer system; FBS ± fetal bovine serum; FCCP ± carbonyl cyanide-4-
(trifluoromethoxy)-phenylhydrazone; GLUT ± glucose transporter; HG ± high glucose medium (25 
mM); IMM ± inner mitochondrial membrane; lncRNA ± long non-coding RNA; NG ± normal glucose 
medium (5.5 mM); NRF ± nuclear respiratory factor; Omy ± oligomycin; PGC-Į ± peroxisome 
proliferator-activated receptor (PPAR) gamma coactivator 1-Į; PI3K ± phosphatidylinositol 3-kinase; 
Q ± quercetin; Q3S ± quercetin 3ƍ-O-sulfate; Q3G ± quercetin 3-O-ȕ-D-glucuronide; RGMB ± 
repulsive guidance molecule family member b; AS1 ± anti-sense 1; Rot ± rotenone; ROS ± reactive 
oxygen species; ROX ± residual oxygen consumption; SIRT ± sirtuin; TBP ± TATA-box binding 
protein; TFAM ± mitochondrial transcription factor A; TR-FRET ± time-resolved fluorescence energy 
transfer.  
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Introduction 
Hyperglycemia is characteristic of type 2 diabetes and the metabolic syndrome, where high 
levels of glucose in the blood lead to intracellular oxidative stress, especially in tissues involved in 
glucose metabolism [1-3]. Although mitochondria are a source of oxidative stress, they are also a 
principal target of attack by reactive oxygen and nitrogen species [4, 5] and, once above certain 
thresholds, insulin sensitivity and secretion are hampered [6, 7]. Complex I of the electron transfer 
system (ETS) is a major source and target of mitochondrial superoxide generation [8, 9] and is 
therefore central to high glucose-induced oxidative stress [1, 10], while surplus glucose and 
accumulating NADH can overload complex I and cause excess superoxide generation [1, 11]. 
Associated mitochondrial dysfunction exacerbates the stress further in a downward spiral linked with 
a perturbation in glucose and lipid oxidation [10-14]. The cause-effect relationship between 
mitochondrial dysfunction and insulin resistance is still debated [15], but it is likely they both occur at 
least in part as a result of the high glucose stress. 
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Quercetin is a well-studied flavonoid that transiently accumulates in mitochondria [16] 
following rapid passive cellular uptake or local de-conjugation of quercetin metabolites, especially at 
sites of inflammation [17-19]. Quercetin has been shown to exert an effect on mitochondrial function 
both directly and indirectly through signalling pathways associated with biogenesis, metabolic flux, 
respiration, mitochondrial membrane potential and apoptosis [16, 20, 21]. Studies in rat pancreatic 
cells suggest quercetin can improve mitochondrial bioenergetics by increasing respiration coupling 
efficiency [22] while in primary cortical neuronal cells quercetin enhanced respiratory capacity and 
cell survival [23]. Quercetin has also been shown to stimulate mitochondrial metabolic signalling 
pathways [23], and to increase PGC-Į15)-1 and TFAM mRNA both in HepG2 cells and mouse 
primary hepatocytes [24, 25]. 
At the same time quercetin and other flavonoids are also known to influence glucose in the 
intestine through modulation of carbohydrate digestion and absorption [26-28] and thus affect hepatic 
glucose, and expression of glycolytic genes in the liver [29]. In streptozotocin-induced diabetic rats, 
quercetin dose-dependently decreased blood glucose, cholesterol and triglycerides [30] alongside 
hepatic oxidative stress markers [31], while it increased hepatic glucokinase activity [30]. Such 
bioactivities have attracted research in the potential application of quercetin in the prevention and 
management of type 2 diabetes [32, 33], but data on its mechanism of action in high glucose stress 
environments is lacking.  
The majority of previous in vitro studies examining the effects of quercetin on mitochondria 
have often employed acute treatments directly to isolated organelles [34-36], and overlooked longer-
term effects in intact cells. In isolated rat brain mitochondria, quercetin lowered hydrogen peroxide 
production and inhibited complex I, while the latter was reversed by addition of coenzyme Q10 (CoQ) 
[34]. In comparison, in isolated mitochondria from rat duodenum quercetin protected complex I from 
inhibition by non-steroidal anti-inflammatory drugs, suggesting a CoQ-like function [35]. To enhance 
understanding of the role of quercetin on maintaining mitochondrial function, we evaluated its dose-
dependent effects, following chronic application of up to 24 h, on mitochondrial respiration in an 
immortalized human hepatic cell model stressed by chronic high glucose. 
Several studies have linked cancer phenotype progression, generally relying on fast glucose 
turnover and glycolysis, with expression levels of repulsive guidance molecules (RGM) [37-39]. The 
biological function of RGMs, a recently discovered family of glycosylphosphatidylinositol-linked 
cell-membrane-associated proteins, remains largely elusive but recent work has unveiled a discrete 
tissue-specific pattern of gene and protein expression for each member (a, b, c) [37]. RGMb is 
VSHFLILFDOO\ WKRXJKW WR UHJXODWH UHVSLUDWRU\ LPPXQLW\ ZKLOH LW¶V ORQJ QRQ-coding RNA (lncRNA) 
RGMB-AS1 is lowly expressed in hepatocellular carcinoma tissues and cell lines [40, 41] and, as 
such, gain-of-function studies showed that up-regulation of lncRNA RGMB-AS1 suppressed 
proliferation, migration and invasion of hepatocellular carcinoma cells such as HepG2 and promoted 
cell apoptosis [40]. The effects of quercetin on RGMb and RGMB-AS1 are yet to be determined. We 
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demonstrate a link between oxidative signalling pathways and changes in mitochondrial respiration 
and metabolic phenotype in the glycolytic environment of HepG2 cells following chronic quercetin 
treatment, with an associated effect on RGMB(-AS1). 
 
Materials and Methods 
Chemical compounds and reagents 
All cell culture medium components, quercetin 3-O-ȕ-D-glucuronide and other reagents were 
from Sigma-Aldrich (Gillingham, UK) unless otherwise stated. Quercetin was from Extrasynthese 
(Genay, France) and quercetin 3ƍ-O-sulfate was synthesised in house [42]. TrypLE Express and Pierce 
Coomassie (Bradford) Protein Assay Kit (#23200) were from Thermo Fisher Scientific (Paisley, UK). 
Mouse anti-NDUFB8 (ab 110242) was from Abcam (Cambridge, UK) and NADH was from VWR 
(Lutterworth, UK). FAM-labelled Taqman primers for PPARGC-Į (PGC-Į, Hs01016719_m1), 
Repulsive guidance molecule b (RGMB, Hs00543559_m1), RGMB antisense RNA 1 (RGMB-AS1, 
Hs04273852_m1) and VIC-labelled primer for TATA-box binding protein (TBP) primer 
(Hs00427620_m1) were from Life Technologies (Thermo Fisher Scientific). Droplet digital PCR 
(ddPCR) Supermix for Probes (no dUTP) and all other materials used for ddPCR were from Bio-Rad 
(Watford, UK). High purity water 0ȍFP-1) supplied by a MilliQ system (Merck Millipore UK, 
Watford, UK) was used throughout this work.  
Cell culture 
HepG2 cells purchased from the American Type Culture Collection (HB-8065, LGC 
Promochem, Teddington, UK) were maintained in (DJOH¶V minimum essential medium (EMEM) 
containing 5.5 (normal) or 25 mM (high) glucose, supplemented with 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, 2% (v/v) non-essential amino 
acids, and 1% (v/v) sodium pyruvate. Cells were seeded in 75 cm2 flasks, 6-well or 24-well plates 
(Appleton Woods, UK) at 8 x 104 cells cm-2 and kept in a humidified atmosphere of 5% CO2/95% air 
at 37°C. The EMEM medium was supplemented with additional glucose DQGILOWHUHGWKURXJKDȝP
PTFE filter (Corning, UK) for high glucose conditions. 
 
Trypan Blue exclusion cell viability assay 
HepG2 cells were seeded in 75 cm2 flasks or 6-well plates and maintained in normal or high 
glucose for 96 h. Medium was changed at 48 h after seeding and at 72 h cells were treated with 10 or 
20 µM quercetin (or 0.1% DMSO controls) in full medium without FBS. After the 24 h treatments 
cells were lifted with 0.25% trypsin-EDTA or TrypLE Express, resuspended in 1 ml medium and an 
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aliquot mixed 1:1 (v/v) with 0.4% Trypan Blue-PBS. Resuspended cells were counted and assessed 
for Trypan Blue exclusion using a TC10 automated cell counter (Bio-Rad Laboratories, Hercules, CA, 
USA). Viable cells excluding Trypan Blue were expressed as a percentage of total cells counted.  
 
Isolation of submitochondrial particles 
HepG2 cells were seeded in 75 cm2 flasks and grown in normal or high glucose for 96 h. Cells 
were treated with 2.5, 5, 10 or 20 µM quercetin (or 0.1% DMSO controls) for the final 24 h, scraped 
into 1 ml PBS supplemented with 1% (v/v) protease inhibitor cocktail (P8340, Sigma-Aldrich, UK), 
centrifuged at 210x g (4oC, 5 min) and snap-frozen in ethanol over dry ice. Cell pellets were stored at 
-80oC until mitochondrial isolation. Submitochondrial particles were prepared from thawed cell 
pellets following three freeze-thaw cycles [43-45], homogenisation with a Dounce homogenizer and 
differential centrifugation using the Mitochondria Isolation Kit for Cultured Cells (ab 110171, 
Abcam, UK) following the manXIDFWXUHU¶VSURWRFROJXLGHOLQHV but with an extra centrifugation step 
(1000x g, 4oC, 5 min) at the end, for a purer preparation. Mitochondrial pellets were resuspended in 
250 mM sucrose, 10 mM HEPES, 50 mM Tris buffer (pH 7.4) supplemented with 1% (v/v) protease 
inhibitor cocktail. 
 
Submitochondrial fraction purity assessment 
Aliquots of the initial cell lysate and the isolated submitochondrial particles of HepG2 cells 
were analysed for NDUFB8 (a subunit of complex I) levels by ProteinSimple Wes automated western 
blotting (ProteinSimple, Bio-Techne, CA, USA) DFFRUGLQJWRWKHPDQXIDFWXUHU¶VJXLGHOLQHV. Samples 
were denatured at 37oC for 20 min and applied at 4.8 mg protein /ml with primary mouse anti-
NDUFB8 at 1/50 dilution and chemiluminescence detected in the multi-image analysis mode. Data 
are presented as chemiluminescence peaks and in the traditional Western gel-like image view 
(Compass Software, Bio-Techne). 
 
Complex I activity assay 
Submitochondrial particles from HepG2 cells grown in normal or high glucose for 96 h and 
treated with varying concentrations of quercetin for the final 24 h were isolated as described above 
and assayed for complex I specific activity spectrophotometrically in 96-well plates on a PheraSTAR 
FS microplate reader (BMG LabTech, Germany) at 37oC. Submitochondrial particles (10 µg) were 
mixed with 150 µM NADH and 50 µM coenzyme Q1 (analog of coenzyme Q10) and the decrease in 
absorbance at 340 nm was followed for 60 min, as previously described [44-48] following 
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optimisation for sample mass and NADH/CoQ1 concentrations. Specific activity was calculated by 
converting rate of absorbance change into rate of NADH decrease per mg of total protein [43] and 
expressed as % of normal glucose (0.1% DMSO control). 
 
DCFH-DA assay 
HepG2 cells were grown in 6-well plates for 96 h in normal or high glucose and treated for the 
final 2, 12 or 24 h with 2.5, 5, 10 or 20 µM quercetin (or 0.1% DMSO controls). The DCFH-DA 
assay was used to assess oxidative stress as described before [49], but with the following 
modifications. Cells were washed with PBS, incubated with 10 µM DCFH-DA in PBS (37oC, 20 min 
in darkness), washed again and fluorescence of DCF was measured on the PheraStar FS microplate 
reader (BMG LabTech, Germany; Ex/Em = 485/530 nm). Cells were scraped in CellLytic M 
supplemented with 1% (v/v) protease inhibitor cocktail and total protein was measured with the 
Bradford assay [50, 51]. DCF fluorescence, in relative fluorescence units, was corrected for protein 
and expressed as relative DCF fluorescence % in the normal/high glucose controls accordingly. 
 
Citrate synthase activity assay 
Cells were grown in 75 cm2 flasks in normal or high glucose for 96 h, with 10 or 20 µM 
quercetin (or 0.1% DMSO controls) for the final 24 h. Cell pellets, prepared as above for 
mitochondria isolation, were lysed and assayed for citrate synthase activity, a marker for total 
mitochondrial content [52], using the Citrate Synthase Assay Kit (CS0720, Sigma-Aldrich) and 
following tKH PDQXIDFWXUHU¶V instructions. Briefly, formation of the 5-thio-2-nitrobenzoic acid 
colorimetric reaction product was followed on the PheraStar FS microplate reader at 412 nm (30oC, 5 
min) and again after addition of oxaloacetic acid. Citrate synthase activity was calculated by 
correcting for the initial reaction rate, a baseline of endogenous thiol/deacetylase levels, and for total 
protein prior to the assay. 
 
High-resolution respirometry 
HepG2 cells, treated as for the citrate synthase assay, were washed in PBS, lifted from 75 cm2  
flasks using TrypLE Express and resuspended in serum-free medium at 1.5 x 106 cells/ml. Oxygen 
concentration and flux were continuously measured following addition of 2 ml of the cell suspensions 
to each chamber of the Oxygraph-2k (O2k) (OROBOROS Instruments, Innsbruck, Austria), 
maintained at 37oC. A phosphorylation control protocol was followed [53, 54]. Routine respiration 
was initially recorded, followed by Leak measurement after addition of 250 nM oligomycin; titration 
with FCCP (carbonyl cyanide-4-(trifluoromethoxy)-phenylhydrazone) (5 µM, 3-5 µl) for ETS 
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capacity; and addition of 1.25 µM rotenone and 2.5 µM antimycin A for assessment of residual 
oxygen consumption (ROX). Additional experiments were conducted whereby quercetin (10-100 µM) 
was titrated directly into the respirometer chamber containing a HepG2 cell suspension, followed by 
FCCP positive control, to assess if quercetin was acting as a direct ETS uncoupler. As a control for 
the effect of quercetin reacting directly with oxygen, quercetin (10-200 µM) was also titrated into 
cell-free medium. 
 
Cellular NAD+/NADH assay 
Cells were grown in 24-well plates and treated as described above for the DCFH-DA assay. 
Cells were washed in PBS, lysed and collected, and NAD+/NADH was measured using a 
Fluorometric Assay Kit (ab 176723, Abcam, UK), in which enzymes specifically recognise NAD+ or 
NADH in an enzyme cycling reaction. According to PDQXIDFWXUHU¶V instructions, lysates were 
transferred to a black, clear-bottomed 96-well plate (Greiner Bio-One, Stonehouse, UK) and, after 
incubation for 60 min at RT, fluorescence signals were collected on the PheraSTAR FS (Ex/Em = 
540/590 nm). 
 
RNA isolation and cDNA synthesis 
Cells were grown in normal or high glucose in 6-well dishes for 60 h. At 60 h cells were 
transferred to medium ± FBS for 12 h (72 h) before treatment with 20 µM quercetin (or 0.1% DMSO 
controls) for up to a further 24 h. Samples were collected after 1, 3, 6, 12 and 24 h. Additional 
samples were collected at 60 h (-12 h) and 72 h (time 0) in order to assess whether the absence of FBS 
had an effect on mRNA expression. Total RNA was isolated using the Aurum Total RNA Mini Kit 
(#732-6820, Bio-Rad Laboratories, UK) DQGIROORZLQJWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV. RNA content 
was determined spectrophotometrically at 260 nm on a NanoDrop (Thermo Fisher Scientific) and 
cDNA was synthesised from 1 µg RNA using a High Capacity RNA-to-cDNA kit (Applied 
Biosystems, Thermo Fisher Scientific), following the PDQXIDFWXUHU¶Vguidelines. 
 
Droplet digital PCR analysis 
The QX100 Droplet Digital PCR system (Bio-Rad Laboratories, USA) was used to quantify 
changes in gene expression of PGC-Į, RGMB, RGMB-AS1 and TBP (housekeeping gene) as 
previously described [55]. Primers of  PGC-Į, RGMB, RGMB-AS1 were mixed with TBP Taqman 
primer in a 20 µl assay (1 µl of each) that contained 10 µl of ddPCR Supermix and 8 µl of cDNA 
diluted with MilliQ water. The mixtures were dispersed into oil droplets using the QX100 Droplet 
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generator and then transferred to a C1000 Touch thermal cycler (Bio-Rad Laboratories, USA). 
Droplet-containing mixtures were incubated for 10 min at 95oC, followed by 40 cycles of 0.5 min at 
94oC and 1 min at 57.8oC, and finished with 10 min incubation at 98oC. Products were maintained at 
12oC before analysis on a QX100 Droplet Reader. The QuantaSoft software (Koãice, Slovakia) was 
used to analyse the data and determine concentrations of the target DNA in copies per µl from the 
fraction of positive reactions using Poisson distribution analysis. Data were collected independently 
for each target and TBP and are presented as fold-change of control treatment.  
 
PPARĮ coactivator recruitment assay 
7KHSRWHQWLDORITXHUFHWLQWRELQGWR33$5ĮDQGDIIHFWFRDFWLYDWRU(PGC1-Įrecruitment was 
tested both in the agonist and antagonist mode with a LanthaScreen TR-FRET (time-resolved 
fluorescence energy transfer) assay (#PV4684, Invitrogen, Thermo Fisher Scientific, UK) according 
WRVXSSOLHU¶VJXLGHOLQHV%ULHIO\33$5ĮOLJDQGELQGLQJGRPDLQWDJJHGZLWKJOXWDWKLRQH-S-transferase 
(GST) was added HLWKHUWR*:33$5ĮDJRQLVW positive control), GW9662 (antagonist positive 
control), quercetin, quercetin 3ƍ-O-sulfate or quercetin 3-O-ȕ-D-glucuronide, followed by the addition 
of pre-mixed fluorescein- PGC-1ĮFRDFWLYDWRUSHSWLGHLQP0+(3(6S+DQGLanthaScreen 
terbium-labelled anti-GST antibody (in 137 mM NaCl, 2.7 mM KCl, 10 mM HEPES, pH 7.5). 
Following optimization by comparison of achieved Zૼ values FDOFXODWHG E\ XVLQJ WKH ³PD[LPXP
DJRQLVW´RU³PD[LPXPDQWDJRQLVW´ DQG³QRDJRQLVW´RU³QRDQWDJRQLVW´FRQWUROGDWD [56], incubation 
was set at 3 h for the agonist mode assays and at 2 h for the antagonist mode (both at room 
temperature). The TR-FRET ratio was calculated by dividing the Em at 520 nm by the Em at 490 nm 
measured on a PheraStar FS microplate reader with a LanthaScreen filter module. The EC50 and IC50 
values were calculated by GraphPad Prism 6 after fitting the data on an equation for a sigmoidal dose 
response. 
 
Statistical analysis 
Data are expressed as means ± standard error of the mean. The significance of differences 
between groups of treatments was analysed by one-way ANOVA and post hoc 7XNH\¶V'XQQHWW¶VRU
two-tailed t-tests as indicated, ZLWK YDULDQFH FKHFNV XVLQJ /HYHQH¶V WHVW DQG with Bonferroni 
correction when multiple treatments were compared with an independent samples Student t-test, using 
SPSS 24.  
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Results 
Quercetin restores complex I activity compromised by chronic high glucose stress  
The mitochondria isolation procedure yielded a highly purified fraction as confirmed by 
NDUFB8 (a subunit of complex I) expression (Fig. 1A). Complex I activity, as assessed by NADH 
oxidation in mitochondria isolated from HepG2 cells (Fig. 1B), decreased by 11% (p < 0.001) 
following high glucose for 24 h and by 19% (p < 0.001) after 96 h when compared to control cells. 
Both hydrogen peroxide and serum absence also decreased complex I activity, while, as expected, it 
was higher in cells grown in galactose-containing medium (Fig. 1C-D). In normal glucose, quercetin 
treatment (2.5-20 µM) caused a small decrease in complex I activity, comparable in all tested 
concentrations. However, in high glucose, quercetin up to 10 µM dose-dependently attenuated the 
high glucose-induced damage; a 94% recovery was found with 10 µM (p < 0.001) while at 20 µM the 
effect was less pronounced (Fig. 1E).  
 
Quercetin lowers concentration of several ROS species in normal and high glucose 
High glucose treatment for 96 h increased DCF fluorescence by 10% (p < 0.01) (Fig. 2A), 
indicating higher levels of some ROS species and an environment with increased oxidative stress. 
This was attenuated in both normal and high glucose conditions dose-dependently by quercetin (2.5-
20 µM) at all the time points tested, up to 24 h (Fig. 2B-D). The effect of quercetin on DCF 
fluorescence was most evident at earlier time points, with a maximum lowering effect of 53% in 
normal (p < 0.001) and 57% in high glucose (P < 0.001) after treatment with 20 µM quercetin for 2 h 
(Fig. 2B). This highly significant decrease of ~45% in the DCF fluoresce signal in both normal and 
high glucose conditions is indicative that some ROS species were decreased, and this decrease was 
not significantly different between normal and high glucose with any dose of quercetin at 2 h (Fig. 
2B). Quercetin effects were less evident at later time points, particularly in the high glucose (Fig. 2C-
D). Although we observed changes at 2.5 PM and above, in subsequent experiments we chose to test 
10 and 20 PM quercetin to clarify the mechanism of protection against high glucose. 
 
Quercetin decreases mitochondrial content while increasing cell viability 
Growing cells in normal or high glucose did not affect citrate synthase activity, a mitochondrial 
matrix marker, whereas quercetin significantly lowered citrate synthase activity after 24 h in normal 
glucose at 10 and 20 µM by 5 and 7% (p < 0.05) respectively. In high glucose an effect was observed 
only with the 20 µM treatment (5%, p < 0.05) (Fig. 3A). Cell viability, assessed by Trypan Blue 
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exclusion, was also not affected by glucose but dose-dependently increased by quercetin, by up to 5% 
in high glucose (p < 0.001) (Fig. 3B).  
 
Quercetin lowers high glucose-induced proton leak and increases oxidative respiration 
Inner mitochondrial membrane (IMM) proton leak, was 21% (p < 0.05) higher in high glucose-treated 
cells, which was reflected in lower coupling efficiency (p < 0.01), but without significant changes in 
basal Routine respiration, non-coupled ETS capacity, or non-ETS residual oxygen consumption 
(ROX). Despite less efficient coupling, mitochondrial ATP production was unaffected (Fig. 4B). 
Respiration in normal glucose was unchanged by quercetin, but Leak was hormetically suppressed (p 
< 0.01) and coupling efficiency was higher with 10 µM accordingly (p < 0.05) (Fig. 4C). Quercetin 
treatment dose-dependently reversed the high glucose-induced proton Leak (p < 0.01) (Fig. 4D) while 
10 µM quercetin also increased oxidative respiration; both the basal cellular and the oligomycin-
VHQVLWLYHµ1HW¶PLWRFKRQGULDOUHVSLUDWLRQ(calculated from (Routine-Leak)/ETS) (p < 0.01). Moreover, 
mitochondrial ATP production was enhanced (p < 0.01) and coupling efficiency recovered (p < 0.001) 
(Fig. 4D). A similar effect was not evident with 20 µM quercetin treatment (Fig. 4D). In general, 
following quercetin treatment, ETS capacity was either unchanged (normal glucose, 10 µM quercetin) 
or mildly lower (both in normal and high glucose), and ROX was dose-dependently decreased in both 
normal and high glucose (Fig. 4C-D). 
 
Quercetin does not uncouple mitochondrial respiration 
When added directly to cell-free medium in the respirometer, quercetin dose-dependently 
reacted with oxygen (Fig. 5A). When added to HepG2 cells in suspension and equilibrated in the 
respirometer chamber, the increase in oxygen consumption was no longer evident, indicating 
quercetin did not react with oxygen in the medium in the presence of the cells, but was rather rapidly 
taken up. In the cellular environment quercetin did not act as a direct ETS uncoupler, unlike FCCP 
(Fig. 5B). 
 
Quercetin reversed the decreased NAD+/NADH in high glucose within 2 h 
 High glucose increased cellular NADH (p < 0.001) (Fig. 6A), but this was blunted at later 
time-points. Quercetin dose-dependently increased NAD+/NADH in high glucose after 2 h (p < 0.01), 
but not in normal glucose (Fig. 6A). NAD+/NADH was elevated after 12 h with 10 µM quercetin in 
both normal and high glucose (p < 0.001) (Fig. 6B) and this effect was maintained in normal glucose 
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up to 24 h (p < 0.001) (Fig. 6C). In high glucose, an effect was evident with 20 µM quercetin at 24 h 
(p < 0.05). 
 
Quercetin increased PGC-1Į, RGMB and RGMB-AS1 mRNA 
Absence of serum increased PGC-Į mRNA expression under both normal and high glucose 
conditions (Fig. 7A, 7C) while RGMB and RGMB-AS1 mRNA levels were not affected by either 
(Fig. 9, 10-panels A, C). Following 12 h in serum-free medium (time 0) PGC-Įincreased by 1.7-fold 
(p < 0.001) and remained stable for 12 h in normal glucose before returning to basal levels by 24 h 
(Fig. 7A). In the presence of high glucose a further increase was evident at 6 h (2-fold), while at 24 h 
mRNA levels were significantly lower than in control cells (Fig. 7C). Treatment with 20 µM 
quercetin increased PGC-Į gene expression within 1 h in normal glucose (p < 0.001) and within 6 h 
in high glucose (p < 0.001). A maximal approximately 2-fold effect was reached at 6 h in both normal 
and high glucose (Fig. 7E, 7G). Quercetin increased RGMB mRNA ~5-fold after 3 h (p < 0.001) (Fig. 
9E, 9G) and RGMB-AS1 ~3.5-fold after 6 h (p < 0.001) (Fig. 10E, 10G), similarly in normal and high 
glucose. Increased mRNA levels of RGMB and RGMB-AS1 were maintained until at least for 12 h. 
As the droplet digital PCR technique determines the absolute number of mRNA molecules in the 
reaction, employing a stably expressed reference gene is not essential but TBP was used to account 
for variations in the sample preparation and to provide comparison between different conditions. TBP 
was mildly affected by the absence of serum and the high glucose conditions and therefore was 
reported separately (Fig. 7, 9, 10- B, D, F, H) to avoid bias of the results. TBP signals were similar 
when multiplexing with the different primers (PGC-Į, RGMB, RGMB-AS1) in all experiments. 
 
Quercetin GRHVQRWDIIHFW33$5ĮFRDFWLYDWRUUHFUXLWPHQW of PGC1-Į 
A TR-FRET assay was set up to test if quercetin could directly affect binding of PGC-Į WR
33$5ĮThe assay was able to detect binding interactions with high sensitivity and small variability; a 
Zૼ of 0.851 and an EC50 of 1.057 nM was measured for GW7647 (Fig. 8A), and a Zૼ of 0.689 and an 
IC50 of 443.6 nM for GW9662 (Fig. 8B) D NQRZQ DJRQLVW DQG DQWDJRQLVW RI 33$5Į UHVSHFWLYHO\. 
Quercetin was found to exert only minimal effects in the agonist mode DW0p < 0.01) (Fig. 
8C), while it had no effect as an antagonist (Fig. 8D). An EC50 was not calculated for quercetin 
because for the concentrations tested a plateau was not reached (Fig. 8C). Quercetin conjugates, 
quercetin 3ƍ-O-sulfate and quercetin 3-O-ȕ-D-glucuronide, were weaker agonists than quercetin 
aglycone; an increase in fluorescence emission was measured RQO\DW0p < 0.01) (Fig. 8C). 
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Fig. 1. Quercetin dose-dependently recovered complex I activity decreased by high glucose in HepG2 
cells. (A) Purity of isolated mitochondrial fraction (imt). Protein expression of complex I subunit 
NDUFB8 increased when compared to the whole cell lysate (WCL), assessed by ProteinSimple 
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automated Western, with traditional Western blot and pherogram views. (B) Complex I activity in 10 
µg imt assessed with NADH (150 µM) in the presence of coenzyme Q1 (50 µM), and corrected for 
non-mitochondrial oxidation by rotenone-inhibited (2 µM) control. Lines of best fit for mean activity 
± SEM. (C) Complex I activity in cells grown in normal glucose (NG) medium supplemented with 
10% serum for 72 h and then treated for 24 h with high glucose (HG), 0.5 mM hydrogen peroxide 
(H2O2) or serum-free medium. Complex I activity was normalised to the NG control (13.7 ± 0.8 
nmol/min/mg) and data are expressed as mean percentages ± SEM (N/n = 3/9). ***p < 0.001 vs NG 
control. (D) Complex I activity in cells grown for 96 h in NG, HG or 10 mM galactose (Gal); data are 
expressed as mean percentages of NG ± SEM (NG = 8.9 ± 0.9 nmol min-1 mg-1) (N/n = 5/15). *p < 
0.05, *** p < 0.001 vs NG control. (E) Complex I activity in cells grown for 96 h in NG or HG and 
treated for the final 24 h (in the absence of serum) with various concentrations of quercetin (or DMSO 
controls). Data are mean percentages of the NG control ± SEM (NG = 8.6 ± 0.3 nmol/min/mg) (N/n = 
6/18). *p < 0.05, ***p < 0.001 vs NG control; #p < 0.05, ### < 0.001 vs HG control.  
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Fig. 2. Quercetin decreased the relative DCF fluorescence in normal and high glucose HepG2 cells. 
(A) Cells were grown for 96 h in normal (NG) or high (HG) glucose and then incubated with 10 µM 
DCFH-DA (20 min), relative fluorescence of DCF was measured and corrected for total protein. (B-
D) Cells grown in NG or HG for 96 h were treated with quercetin (or DMSO control), in the absence 
of serum, for the final 2 h (B), 12 h (C) or 24 h (D) and DCF measured in the same way. All data are 
mean values expressed as (%) of the NG or HG controls accordingly ± SEM (N/n = 4/12). **p < 0.01, 
***p < 0.001 vs NG controls; #p < 0.05, ##p < 0.01, ###p < 0.001 vs HG controls; NS = not significant. 
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Fig. 3. Quercetin decreased mitochondrial citrate synthase and increased viability in HepG2 cells. (A) 
Mitochondrial citrate synthase activity in cells grown for 96 h in normal (NG) or high (HG) glucose 
and treated for the final 24 h, in the absence of serum, with 10 or 20 µM quercetin (or DMSO 
control). All data are mean values expressed as (%) of the NG control ± SEM (NG = 43.8 ± 0.5 nmol 
min-1 mg-1) (N = 6 for 10 µM; 9 for 20 µM; 15 for controls). *p < 0.05 vs NG control; #p < 0.05 vs HG 
control. (B) Cells were assessed for plasma membrane integrity using the Trypan Blue exclusion test. 
Data are mean values of cells that excluded Trypan Blue expressed as (%) of total cells ± SEM (N = 6 
for 10 µM; 13 for 20 µM; 19 for controls). **p < 0.01 vs NG control; ##p < 0.01 vs HG control; ###p < 
0.001 vs HG control.  
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Fig. 4. Quercetin decreased high glucose-induced IMM proton leak and increased oxidative 
respiration. (A) Typical oxygen flux trace from an experiment using the OROBOROS O2k high-
resolution respirometer (grey line ± [O2]; black line ± O2 flux). Intact HepG2 cells were added to the 
respirometer and, following equilibration, respiration states were measured in turn for Routine 
Respiration, Proton Leak (after addition of oligomycin (250 nM) (Omy)), maximal electron transfer 
system capacity (ETS) (uncoupled by FCCP (5 µM) titration), and non-ETS residual oxygen 
consumption (ROX) (addition of rotenone (1.25 µM) (Rot) and antimycin A (2.5 µM) (AmA)). 
Routine, Leak and ETS data were all ROX-corrected. (B) Respirometry data for cells grown in normal 
(NG) or high (HG) glucose for 96 h. Net ETS Respiration is the net routine flux control ratio, 
calculated as ((Routine-Leak)/ETS), and is the ratio of basal ETS respiration driving mitochondrial 
ATP production as a factor of the maximal ETS capacity. ATP is ATP production, calculated as 
oligomycin-sensitive respiration (Routine-Leak). Coupling efficiency is the ratio of ATP 
production/Routine Respiration. Data shown are mean values and expressed as (%) of the NG control 
± SEM (N = 9). *p < 0.01 vs NG. (C-D) Cells grown in NG (C) or HG (D) for 96 h were treated with 
10 or 20 µM quercetin (Q) (or DMSO controls), in the absence of serum, for the final 24 h. Data are 
mean values and expressed as (%) of the NG or HG control accordingly ± SEM (N = 5 for 10 µM; 9 
for 20 µM; 14 for controls). *p < 0.05, **p < 0.01, ***p < 0.001 vs controls. See Supplementary 
Table 1 for control values.  
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Fig. 5. Quercetin reacts with oxygen and is rapidly taken up by HepG2 cells without uncoupling ETS. 
(A) O[\JHQµIOX[¶ WUDFHIRUcell-free medium when titrated with quercetin (10-200 µM final) in the 
OROBOROS O2k high-resolution respirometer. (B) Intact HepG2 cells were added to the 
respirometer and, following equilibration, quercetin (10-100 µM) was titrated in, followed by a single 
addition of FCCP (5 µM) as a positive control. Grey line ± [O2]; black line ± O2 flux; Q followed by 
number indicates cumulative quercetin concentration (µM).  
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Fig. 6. Quercetin reversed the high glucose-decreased NAD+/NADH ratio in HepG2 cells. (A) Cells 
grown in normal (NG) or high (HG) glucose for 96 h were treated with various concentrations of 
quercetin (or DMSO controls) for the final 2 h. (B-C) NG and HG cells were treated with 10 or 20 
µM quercetin (or DMSO controls) for the final 12 h (B) or 24 h (C). All data are expressed as mean 
NAD+/NADH ± SEM (N/n = 6/36). ***p < 0.001 vs NG control; #p < 0.05, ##p < 0.01, ###p < 0.001 vs 
HG control.  
19 
 
 
20 
 
Fig. 7. PGC-Į and TBP mRNA expression following 12h serum starvation in normal and high 
glucose-treated HepG2 cells (A-D). PGC-Įand TBP mRNA levels following quercetin treatment (E-
H).Cells were seeded in normal (NG) or high (HG) glucose media and after 60 h (T = -12 h) the 
medium was changed to medium ± FBS (F). Cells were treated at 72 h (T = 0 h) with ± FBS and 
lysates for RNA extraction were collected at 6, 12 and 24 h, with additional at -12 and 0 h. (E-H) 
Cells were grown in the same way and treated with serum-free medium from 60 h and with 20 µM 
quercetin (Q) at 72 h (T = 0 h) (or DMSO controls), and samples were collected at 1, 3, 6, 12 and 24 
h. All data are mean values of fold-change in PGC-Į RU 7%3 expression ± SEM (N/n = 6/18) vs 
respective controls. *p < 0.05, **p < 0.01, ***p < 0.001 vs respective control.  
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Fig. 8. Quercetin increased coactivator recruitment of PGC-ĮWR33$5Į in vitro RQO\DW 10 µM. 
(A) An EC50 of 1.057 nM was measured for GW7647. (B) An IC50 of 443.6 nM was measured for 
GW9662. (C) Quercetin (Q), quercetin 3ƍ-O-sulfate (Q3S) and quercetin 3-O-ȕ-D-glucuronide (Q3G) 
were tested in the agonist mode at 0.6-100 µM (A). Letters indicate significant differences between 
tested concentrations compared by one-way ANOVA and Bonferroni correction (p < 0.01). (D) 
Quercetin had no effect as an antagonist at the tested concentrations (0.6-100 µM). All data are mean 
(N/n = 3/18) and error bars represent SEM. 
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Fig. 9. RGMB and TBP mRNA expression in normal and high glucose-treated HepG2 cells. (A-D) 
Cells were seeded in normal (NG) or high (HG) glucose media and after 60 h (T = -12 h) the medium 
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was changed to medium ± FBS (F). Cells were treated at 72 h (T = 0 h) with ± FBS and lysates for 
RNA extraction were collected at 6, 12 and 24 h, with additional at -12 and 0 h. (E-H) Cells were 
grown in the same way and treated with serum-free medium from 60 h and with 20 µM quercetin (Q) 
at 72 h (T = 0 h) (or DMSO controls), and samples were collected at 1, 3, 6, 12 and 24 h. All data are 
mean values of fold-change in RGMB or TBP expression ± SEM (N/n = 6/18) vs respective controls. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs respective control. 
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Fig. 10. RGMB-AS1 and TBP mRNA expression in normal and high glucose-treated HepG2 cells. 
(A-D) Cells were seeded in normal (NG) or high (HG) glucose media and after 60 h (T = -12 h) the 
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medium was changed to medium ± FBS (F). Cells were treated at 72 h (T = 0 h) with ± FBS and 
lysates for RNA extraction were collected at 6, 12 and 24 h, with additional at -12 and 0 h. (E-H) 
Cells were grown in the same way and treated with serum-free medium from 60 h and with 20 µM 
quercetin (Q) at 72 h (T = 0 h) (or DMSO controls), and samples were collected at 1, 3, 6, 12 and 24 
h. All data are mean values of fold-change in RGMB-AS1 or TBP expression ± SEM (N/n = 6/18) vs 
respective controls. *p < 0.05, **p < 0.01, ***p < 0.001 vs respective control.  
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Fig. 11. Proposed mechanisms of action of quercetin in mitochondria in HepG2 cells treated 
chronically with high glucose. (A) Elevated glucose leads to increased NADH and overproduction of 
superoxide (O2-) at complex I of the electron transfer system. (B) Quercetin inhibits complex I at the 
coenzyme Q10-binding site (CoQ), suppresses superoxide generation and attenuates the high glucose-
induced proton leak across the inner mitochondrial membrane, while oxidising NADH and potentially 
allowing electron transfer to continue to complex III. This results in more efficient coupling with ATP 
synthesis. As a result, the NAD+/NADH ratio is increased in parallel with induction of PGC-ĮJHQH
expression by quercetin; mitochondrial function is promoted and metabolic flux shifted to 
mitochondrial respiration, leading to lower oxidative stress and attenuation of high glucose-induced 
mitochondrial dysfunction, with increased net respiration and recovered complex I activity. RGMB 
and RGMB-AS1 (not shown) were increased with PGC-Į LQ FRUUHODWLRQ ZLWK WKH VKLIW IURP
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glycolysis. PDH ± pyruvate dehydrogenase, TCA cycle ± tricarboxylic cycle, Acetyl CoA ± acetyl 
coenzyme A. 
 
Discussion 
High glucose-induced oxidative stress is linked to mitochondrial dysfunction, insulin resistance 
and metabolic syndrome [57]. Quercetin is thought to have a beneficial effect in various aspects of 
these metabolic diseases [20, 25, 31, 32, 58], either through restriction of ROS generation locally, or 
enhancement of cellular oxidative defences [34, 59-62]. Mechanisms of quercetin action have been 
reviewed [20] and it is apparent that information in the high glucose environment, and on longer term 
metabolic effects, remains limited.  
Under conditions of chronic high glucose, serum starvation, or increased oxidative stress 
following treatment with H2O2, ETS complex I activity was decreased in agreement with previous 
reports [63, 64], while activity was increased by galactose, owing to increased oxidative 
phosphorylation fuelled by glutamine and fatty acids [65-68]. We show here that quercetin could 
dose-dependently protect against accumulating ROS and preserve the ETS protein complexes, 
potentially halting damage in mitochondrial DNA that ultimately occurs [4, 5, 8, 69]. We found that 
quercetin was able to relieve complex I from ROS-induced damage, especially under high glucose 
stress. Competitive inhibition of complex I at the CoQ-binding site was previously reported for 
quercetin [70] as well as a complementary activity as a CoQ mimetic, allowing electron transfer to 
continue from NADH to complex III [34, 35, 71]. Quercetin effects were time-dependent, probably 
due to quercetin metabolism, although sustained effects following 24 h after quercetin treatment point 
to metabolic changes. It has been shown that quercetin is almost fully metabolised within 4 h in 
HepG2 cells, while phase II metabolism was attenuated by high glucose [72]. We observed effects 
here even at 2.5 PM quercetin, although many of the mechanistic experiments were performed at 10 
PM to ensure confidence in the results. Most previous publications cited in this paper have used much 
higher concentrations of quercetin. Ultimately, proof of any effect must be shown in vivo, but it is 
helpful to understand the mechanistic aspects using cultured cells. 
A mild but significant decrease in citrate synthase activity was observed by quercetin treatment 
in both normal and high glucose while cell viability and plasma membrane integrity were improved. 
Since high glucose-induced loss of complex I activity was reversed with quercetin, this indicates 
improved mitochondrial function and increased oxidative capacity, limiting aberrant cell proliferation, 
a characteristic of glycolytic HepG2 cells. These results were also corroborated by increased RGMB 
and lncRNA RGMB-AS1 expression, which were previously correlated with decreased HepG2 
proliferation and formation of a smaller number of colonies [40]. RGMb is also thought to reflect 
respiratory immunity in epithelial cells through binding to programmed death ligand 2 (PD-L2), while 
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blockade of the RGMB-PD-L2 interaction markedly impaired the development of respiratory 
tolerance [41]. Lowered mitochondrial content is likely owed to decreased lipogenesis and membrane 
formation, with pyruvate being directed to citrate and to oxidative metabolism rather than lipid 
anabolism; with increased oxidative function the mitochondrial population is streamlined. 
Our hypothesis is also supported by lower proton leak across the IMM and an overall decrease 
in DCF fluorescence, albeit the latter is not exclusively indicative of ROS alone nor informative of 
specific ROS species formed [73], but limitations in this assay are outweighed by the highly 
significant differences observed in cells treated with quercetin and is the decrease is associated with 
the general change in redox status and lower oxidative stress. Previous studies have shown that 
quercetin improves mitochondrial bioenergetics in various other models [22, 23], while a role in 
maintaining membrane integrity has also been hypothesized [74-76]. The lower Leak in high glucose-
treated cells with quercetin led to enhanced mitochondrial respiration by maximizing coupling 
efficiency and was reflected in higher Routine and net ETS respiration, indicative of increased use of 
ETS capacity for ATP turnover [54] as found here. These changes were only evident in the cells 
treated with 10 µM quercetin, while at 20 µM there was a decrease in routine respiration, consistent 
with the hypothesis that complex I may have been inhibited. Previous studies suggested that quercetin 
uncoupled ETS and oxidative phosphorylation while inhibiting mitochondrial respiration in isolated 
mitochondria [77-79]. In intact H9c2 rat cardiomyocytes short-term incubation with quercetin did not 
induce uncoupling, demonstrating that the effects seen in isolated mitochondria are attenuated in 
whole cells [80]. We provide supporting evidence for this here, as quercetin at high concentrations did 
not act as an uncoupler in HepG2 cells. When cells were not present, quercetin reacted with oxygen 
[81]. 
Importantly, the non-ETS residual oxygen consumption (ROX) was dose-dependently 
decreased by quercetin, which is indicative of less dependence on glycolysis. ROX represents the 
combined effect of oxygenase redox enzymes [54, 82, 83] and cell surface oxygen consumption via 
trans-plasma membrane electron transport (tPMET) [84]. Increased NADH oxidation by the actions of 
quercetin, as shown here by an increase in the NAD+/NADH ratio, and via direct inhibition of ATPase 
enzymes [85-88] such as those involved in tPMET could explain our results. Lower dependence on 
glycolysis would be expected if more ATP is generated by quercetin-enhanced mitochondrial 
respiration and oxidation of alternative substrates such as glutamine and fatty acids [53], as shown 
here after 24 h.  
Furthermore, quercetin inhibited glucose-6-phosphatase in insulin-resistant HepG2 cells and 
enhanced insulin sensitivity, allowing glycolysis to continue towards pyruvate [89]. We previously 
showed that 5 µM quercetin had a modest inhibitory effect on glucose uptake and metabolism in 
HepG2 cells over 12 h in normal glucose conditions [90]. However, HepG2 cells are known to be 
highly glycolytic with compromised oxidative phosphorylation, limited PI3K-Akt signalling and 
insulin responses [91]. A sustained decrease in ROS would potentially enhance insulin sensitivity in 
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cells in vivo, although this possibility is difficult to explore in immortalized cell models where glucose 
transport is mainly governed by GLUT1 and to a much lesser extent by insulin-responsive GLUT 
transporters. 
A quercetin-induced increase in cellular NAD+ could give rise to post-translational 
modifications through the AMPK-SIRT-PGC-Į axis, a central regulator of energy metabolism. PGC-
Įhas been linked to mitochondrial biogenesis and function while it is also activated under oxidative 
stress [92-94], and thought to suppresses transcription of glycolytic genes [95]. PGC-Į mRNA was 
increased in response to serum deprivation and further increased by quercetin under both normal and 
high glucose conditions, indicating that glucose concentration is not the critical effector in PGC-Į
induction by quercetin. An increase in PGC-Į transcription corroborates the observed increase in 
NAD+ in cells treated with quercetin, as NAD+-dependent SIRT1 activates PGC-Į, which in turn 
promotes its own transcription [96, 97]. 
Given that quercetin was found to weakly enhance PGC-Į UHFUXLWPHQW WR33$5Į, the main 
upstream nuclear factor regulating genes involved in mitochondrial energy metabolism, at 
concentrations achievable only in the cellular environment, we conclude that the effects of quercetin 
on PGC-Į are most likely via indirect mechanisms and a result of the effects seen on complex I and 
NADH as summarized in Fig. 11. However, we cannot exclude involvement of other transcription 
factors in the transcriptional regulation of PGC-ĮE\TXHUFHWLQ. 
The protective effects of quercetin on mitochondrial bioenergetics in cells stressed by high 
glucose have not been demonstrated previously. Proteomics studies have revealed that complex I is 
lowered in diabetic patients [98], providing a potential target for the protective effects of quercetin 
against developing type 2 diabetes, as observed in epidemiological studies for quercetin-rich foods 
such as apples and tea [99, 100] and for quercetin in animal models of diabetes [101, 102]. The 
notable quercetin-induced increases in RGMB and RGMB-AS1 in HepG2 cells point towards a 
potential mechanism in the disruption of cancer cell proliferation [40], linked to the alteration from 
high dependence on glycolysis. 
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Highlights: 
x Quercetin protects mitochondrial function from high glucose-induced stress  
x Through an increase in repulsive guidance molecule b (RGMB) mRNA and its long non-coding 
RNA, quercetin may initiate a change of the glycolytic phenotype of HepG2 cells. 
x Quercetin reversed chronic high glucose-induced oxidative stress and mitochondrial 
dysfunction 
x Quercetin induced lower ROS in combination with improved complex I activity and ETS 
coupling efficiency  
 
